⌕
Vera Therapeutics · VERA · Nasdaq
Tenet 41 · Weak
Compare
$26.20−2.85%At closeTenet 41 · Weak
$26.20−0.77 (−2.85%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Vera Therapeutics (VERA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+378.1%) and Returns vs FCF (n/m). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼96.9%
−299.6
FY21→FY25CAGR —
Free cash flow ($M)▼78.2%
−241.7
FY21→FY25CAGR —
Diluted EPS▼69.5%
−4.66
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+378.1%

13.4mn → 64.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$630.0K

−35.2% YoY in FY25.

Returns vs FCF
n/m

$0.0M returned vs $−241.7M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−215.3R&D−100.2SG&A−315.5Op income15.9Tax & other−299.6Net income

Margin trend · direction beats level
108530%sector median net margin ~3%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
10,277.00.00.00.00.00.0——
Cost of revenue
3,296.00.00.00.00.00.0——
Gross profit
6,981.00.00.00.00.00.0——
Research & development
246,654.0215,256.0126,172.078,225.068,993.022,484.0▲70.6%+75.9%
Selling, general & admin
187,857.0100,217.040,998.023,787.021,910.011,918.0▲144.4%+70.3%
Total operating expenses
434,511.0315,473.0167,170.0102,012.090,903.034,402.0▲88.7%+74.0%
Operating incomefeeds ROC rank
−427,530.0−315,473.0−167,170.0−102,012.0−90,903.0−34,402.0▼88.7%—
Other income, net
12,218.015,859.015,023.06,023.01,848.01,794.0——
Pretax income
−415,312.0−299,614.0−152,147.0−95,989.0−89,055.0−32,608.0▼96.9%—
Income tax
—1.01.01.01.01.0▲0.0%+0.0%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−415,313.0−299,615.0−152,148.0−95,990.0−89,056.0−32,609.0▼96.9%—
Per share
Diluted EPSbuyback-sensitive
−5.90−4.66−2.75−2.25−3.35−2.43▼69.5%—
Diluted shares (mn)
72.1364.2355.3342.7126.5713.44▲16.1%+47.9%
Margins
Gross margin
67.9%———————
Operating margin
−4160.1%———————
Net margin
−4041.2%———————
† TTM = trailing four quarters through 2026-09-30.
FY20 – FY20 · 1 more year
Unlock the full history →
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.